Your browser doesn't support javascript.
loading
Are stem cell marker expression and cd133 analysis relevant to differentiate colorectal cancer? / A expressão de marcadores de células-tronco e a análise do cd133 são relevantes na diferenciação do câncer colorretal?
Czeczko, Leticia Elizabeth Augustin; Ribas, Carmen Australia Paredes Marcondes; Czeczko, Nicolau Gregori; Skare, Thelma Larocca; Yamakawa, Camila Kienen; Gionedis, Guilherme; Vasconcelos, Cecilia; Bremer, Fabiola Pabst; Castoldi, Diogo Francesco; Gasser, Martin; Waaga-Gasser, Ana Maria.
  • Czeczko, Leticia Elizabeth Augustin; Mackenzie Evangelical Faculty of Paraná. Curitiba. BR
  • Ribas, Carmen Australia Paredes Marcondes; Mackenzie Evangelical Faculty of Paraná. Curitiba. BR
  • Czeczko, Nicolau Gregori; Mackenzie Evangelical Faculty of Paraná. Curitiba. BR
  • Skare, Thelma Larocca; Mackenzie Evangelical Faculty of Paraná. Curitiba. BR
  • Yamakawa, Camila Kienen; Mackenzie Evangelical Faculty of Paraná. Curitiba. BR
  • Gionedis, Guilherme; Mackenzie Evangelical Faculty of Paraná. Curitiba. BR
  • Vasconcelos, Cecilia; Mackenzie Evangelical Faculty of Paraná. Curitiba. BR
  • Bremer, Fabiola Pabst; Mackenzie Evangelical Faculty of Paraná. Curitiba. BR
  • Castoldi, Diogo Francesco; Mackenzie Evangelical Faculty of Paraná. Curitiba. BR
  • Gasser, Martin; Mackenzie Evangelical Faculty of Paraná. Curitiba. BR
  • Waaga-Gasser, Ana Maria; Harvard Medical School. Brigham and Womans Hospital. Renal Division. Boston. US
ABCD (São Paulo, Impr.) ; 34(2): e1585, 2021. tab, graf
Article in English, Portuguese | LILACS | ID: biblio-1345003
ABSTRACT
ABSTRACT

Background:

CD133 and AXL have been described as cancer stem cell markers, and c-MYC as a key regulatory cellular mechanism in colorectal cancer (CRC).

Aim:

Evaluate the prognostic role of the biomarkers CD133, AXL and c-MYC and their association with clinicopathologic characteristics in colorectal adenocarcinomas and adenomas.

Methods:

A total of 156 patients with UICC stage I-IV adenocarcinomas (n=122) and adenomas (n=34) were analyzed. Tissue microarrays (TMA) from primary tumors and polyps for CD133, c-MYC and AXL expression were performed and analyzed for their significance with clinicopathologic characteristics.

Results:

Poorly differentiated adenocarcinomas and disease progression were independent risk factors for poor overall survival. The median overall survival time was 30 months. Positive CD133 expression (35.9% of all cases), particularly of right-sided CRCs (44.8% of the CD133+ cases), was negatively correlated with death in the univariate analysis, which did not reach significance in the multivariate analysis. c-MYC (15.4% of all cases) was predominantly expressed in advanced-stage patients with distant (non-pulmonary/non-hepatic) metastasis. AXL expression was found only occasionally, and predominantly dominated in adenomas, with less penetrance in high-grade dysplasia.

Conclusions:

CD133 expression was not associated with inferior overall survival in CRC. While AXL showed inconclusive results, c-MYC expression in primary CRCs was associated with distant metastasis.
RESUMO
RESUMO Racional CD133 e AXL são descritos na literatura como marcadores de células-tronco tumorais, e c-MYC cumpre papel chave como mecanismo de regulação celular no câncer colorretal (CCR).

Objetivo:

Avaliar o papel prognóstico dos biomarcadores CD133, AXL e c-MYC e sua associação com características clinicopatológicas de adenocarcinomas e adenomas colorretais.

Métodos:

Um total de 156 pacientes com adenocarcinomas de estádio UICC I-IV (n=122) e adenomas (n=34) colorretais foram avaliados. Microarranjos teciduais (TMA) dos tumores primários e adenomas foram realizados em busca de expressão de CD133, c-MYC e AXL, com posterior análise de relação significativa com características clinicopatológicas.

Resultados:

Adenocarcinomas pobremente diferenciados e progressão de doença foram fatores de risco independentes para má sobrevida global. A taxa mediana de sobrevida global foi de 30 meses. Expressão positiva de CD133 (35,9% dos casos), particularmente em cânceres de cólon direito (44,8% dos casos CD133+), correlacionou-se negativamente com óbito na análise univariada, sem significância estatística na análise multivariada. c-MYC (15,4% dos casos) teve predomínio de expressão em pacientes com estádio avançado com metástases distantes (não-pulmonares/não-hepáticas). Expressão de AXL foi pouco encontrada, com predomínio em adenomas, com menor penetrância em displasia de alto grau.

Conclusão:

Expressão de CD133 não se associou com sobrevida global inferior em CCR. Enquanto AXL demonstrou resultados inconclusivos, expressão de c-MYC em tumores primários se associou-se à metástases à distância.
Subject(s)


Full text: Available Index: LILACS (Americas) Main subject: Colorectal Neoplasms / Biomarkers, Tumor Type of study: Prognostic study / Risk factors Limits: Humans Language: English / Portuguese Journal: ABCD (São Paulo, Impr.) Year: 2021 Type: Article Affiliation country: Brazil / United States Institution/Affiliation country: Harvard Medical School/US / Mackenzie Evangelical Faculty of Paraná/BR

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Index: LILACS (Americas) Main subject: Colorectal Neoplasms / Biomarkers, Tumor Type of study: Prognostic study / Risk factors Limits: Humans Language: English / Portuguese Journal: ABCD (São Paulo, Impr.) Year: 2021 Type: Article Affiliation country: Brazil / United States Institution/Affiliation country: Harvard Medical School/US / Mackenzie Evangelical Faculty of Paraná/BR